PALI.US Palisade Bio Inc

Healthcare Biotechnology USA Stocks
1.12 USD
Close of Nov 15, 2026
1.01 2.86
Market cap
USD 201M
P/E
1.2x
P/B
1.79x
ROE
-41.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PALI.US undervalued?

Graham number

The Graham number of Palisade Bio Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Palisade Bio Inc fundamental analysis

No fundamental analysis for Palisade Bio Inc yet.

Palisade Bio Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Palisade Bio Inc

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agre…

Full company profile